SHP Financial Share News Feed - London South East

Glance-STOCKS NEWS EUROPE-UK drugmaker Shire falls ahead of R&D day

Mon, 17 Nov 2008 10:26:13 GMT

STOCKS NEWS Reuters Results diary Stocks on the move Real-time Equity News

BRIEF-Shire settles former TKT shareholder appraisal rights litigation

Wed, 05 Nov 2008 19:52:49 GMT

Nov 5 (Reuters) - Shire Plc: * Shire successfully settles former TKT shareholder appraisal rights litigation

UPDATE 2-Shire Q3 in line but dollar may hurt in 2009

Wed, 29 Oct 2008 14:12:53 GMT

LONDON, Oct 29 (Reuters) - Britain's third-biggest drugmaker Shire unveiled third-quarter results broadly in line with expectations on Wednesday, driven sales of hyperactivity medicines and new products.

UPDATE 1-Shire third-quarter results meet expectations

Wed, 29 Oct 2008 12:34:33 GMT

LONDON, Oct 29 (Reuters) - Britain's third biggest drugmaker Shire saw third-quarter sales come in broadly in line with analysts' expectations, driven by sales of its hyperactivity medicines.

BRIEF-Shire Q3 revenues up 28% at $779 million

Wed, 29 Oct 2008 12:22:36 GMT

LONDON, Oct 29 (Reuters) - Shire Plc: * Q3 total revenues up 28% to $779 million vs consensus forecast $769 million

SHIRE PLC - PRODUCT SALES UP 31% TO $713 MILLION

Wed, 29 Oct 2008 12:19:57 GMT

NEW YORK (Thomson Financial) - SHIRE PLC - PRODUCT SALES UP 31% TO $713 MILLION Chuck Mikolajczak

STOCKS NEWS EUROPE-Europe stock futures leap after US, Asia soar

Wed, 29 Oct 2008 07:41:11 GMT

- STOCKS NEWS Reuters Results diary Stocks on the move Real-time Equity News

UPDATE 1-Shire awaits more data on Renovo's Juvista

Thu, 28 Aug 2008 12:29:56 GMT

LONDON, Aug 28 (Reuters) - Renovo Group Plc , the British scar reduction specialist, said on Thursday that Shire Ltd would not push ahead immediately with final-stage trials on its Juvista product, despite promising Phase II test results.

Shire says has acquired 81 pct of Jerini

Wed, 13 Aug 2008 16:23:09 GMT

LONDON (Thomson Financial) - Shire Limited, the global specialty biopharmaceutical company, said it has since July 3 acquired 81 percent of the shares in Jerini AG through its wholly owned indirect subsidiary Shire Deutschland Investments GmbH, which today also published an offer document in r

Shire says chairman Emmens exercise options over 37,222 shares, retains all

Wed, 06 Aug 2008 15:32:16 GMT

LONDON (Thomson Financial) - Shire Ltd., the global specialty biopharmaceutical company, said its chairman Matthew Emmens exercised options over 37,222 shares at various prices and retains all the shares resulting from the exercise.

RPT Shire ups full-year sales guidance to 20 percent after strong Q2 UPDATE

Thu, 31 Jul 2008 13:54:58 GMT

(Repeating to clarify first sentence) LONDON (Thomson Financial) - Shire Ltd. upped its guidance for 2008 revenue growth to at least 20 percent above year ago-levels, as it delivered a 35 percent rise in second-quarter sales.

Shire ups its full-year sales guidance to 20 percent after strong Q2 UPDATE

Thu, 31 Jul 2008 11:56:35 GMT

(Recasts, adds CEO comment, detail) LONDON (Thomson Financial) - Shire Ltd. upped its guidance for 2008 revenue growth be at least 20 percent above year ago-levels, as it delivered a 35 percent rise in second-quarter sales.

Shire ups FY revenue guidance as Q2 sales rise 35 percent

Thu, 31 Jul 2008 11:29:53 GMT

LONDON (Thomson Financial) - Shire Ltd. upped its guidance for 2008 revenues to be at least 20 percent above year ago-levels as it delievered a 35 percent rise in second-quarter revenue.

London shares outlook - higher after Wall St gains; HBOS, Shell numbers in focus

Thu, 31 Jul 2008 06:19:29 GMT

LONDON (Thomson Financial) - Leading shares are expected to open a touch firmer Thursday, building on Wall Street's gains overnight but with sentiment tempered following worse than expected UK consumer confidence data, with HBOS, Royal Dutch Shell and AstraZeneca among those reporting numbers.

Shire non-executive director Robin Buchanan to step down on July 29

Mon, 21 Jul 2008 11:28:52 GMT

LONDON (Thomson Financial) - Biopharmaceutical company Shire Limited said non-executive director Robin Buchanan will step down from the board of directors on July 29 2008, on the completion of his term of office.

Shire says EU approves Jerini's Firazyr

Tue, 15 Jul 2008 14:01:44 GMT

LONDON (Thomson Financial) - Jerini AG, which Shire Ltd. is buying for 328 million euros, has received approval from the European Commission to sell Firazyr to treat acute attacks of hereditary angioedema (HAE), a deficiency of the immune system that causes swelling.

Shire to acquire biotechnology company Jerini for 328 million euros UPDATE

Thu, 03 Jul 2008 09:38:39 GMT

(Adds analyst comment) LONDON (Thomson Financial) - Shire Plc., the specialty pharmaceutical company, is set to acquire Berlin-based biotechnology company Jerini AG in a 328-million-euro deal, with the specific intention of adding Jerini's Firazyr orphan drug product to its portfolio.

Shire to acquire biotechnology company Jerini for 328 million euros UPDATE

Thu, 03 Jul 2008 09:07:16 GMT

(Adds CEO comment, detail throughout) LONDON (Thomson Financial) - Shire Plc., the specialty pharmaceutical company, is set to acquire Berlin-based biotechnology company Jerini AG in a 328-million-euro deal, with the specific intention of adding Jerini's Firazyr orphan drug product to its

Shire to acquire biotechnology company Jerini for 328 million euros

Thu, 03 Jul 2008 08:15:49 GMT

LONDON (Thomson Financial) - Shire Plc, the specialty pharmaceutical company, is set to acquire Berlin-based biotechnology company Jerini AG in a 328 million euros deal, with the specific intention of adding Jerini's Firazyr orphan drug product to its portfolio.

UK drug pricing deal to cut company profits - report

Wed, 18 Jun 2008 06:23:45 GMT

LONDON (Thomson Financial) - New rules on drug pricing to be unveiled by the government on Wednesday are expected to herald fresh cuts in income for the pharmaceutical industry in Britain, reports the Financial Times.

Shire says CFO Angus Russell buys 2,000 ADS at $46.998 each

Mon, 16 Jun 2008 13:37:54 GMT

LONDON (Thomson Financial) - Shire Ltd. said chief financial officer Angus Russell has bought 2,000 American Depository Shares (ADS), representing 6,000 ordinary shares, at $46.998 per ADS.

Shire appoints Graham Hetheringon Chief Financial Officer and Board Director

Tue, 10 Jun 2008 14:36:43 GMT

LONDON (Thomson Financial) - Shire Plc., the specialty pharmaceutical company, has appointed Graham Hetherington Chief Financial Officer and Executive Board Director from July 1.

Renovo Group H1 pretax loss narrows; says financial performance in line UPDATE

Thu, 29 May 2008 12:20:23 GMT

(Adds analyst upgrade, live share price) LONDON (Thomson Financial) - Renovo Group Plc. said its first-half financial performance was broadly in line with its expectations, as it reported a narrower first-half pretax loss due in part to a decline in research and development expenses.

Shire says Hunter Syndrome treatment Elaprase approved in Brazil

Tue, 27 May 2008 06:26:57 GMT

LONDON (Thomson Financial) - Shire Ltd. said its Hunter syndrome treatment Elaprase has been approved in Brazil.

Diageo 'monitoring' UK tax regime, but no immediate plans to switch domicile

Thu, 08 May 2008 07:28:54 GMT

LONDON (Thomson Financial) - Diageo Plc., the international drinks group whose leading brands include Johnnie Walker and Smirnoff vodka, said Thursday it was 'monitoring' the current tax regime in the UK, but that there were no immediate plans to switch its domicile overseas to lessen its tax

UK Court of Appeal orders more transparency in assessments for Alzheimer's drugs

Thu, 01 May 2008 12:08:21 GMT

LONDON (Thomson Financial) - The United Kingdom's medicines assessment agency has been told that it must reveal more details to drug companies and patient groups about how it reaches its cost/benefit recommendations for medicines as the Court of Appeal ruled its current process lacks 'transpar

FOCUS UBM and Shire moving tax bases to Ireland not likely to be isolated cases

Mon, 28 Apr 2008 13:56:36 GMT

LONDON (Thomson Financial) - Plans by United Business Media Plc. and Shire Plc. to relocate their tax bases to Ireland will not be isolated examples, unless the government softens its tax policy on controlled foreign companies, according to a tax partner at KPMG UK.

United Business Media lured abroad by attractive Irish tax regime - report

Mon, 28 Apr 2008 06:10:24 GMT

LONDON (Thomson Financial) - United Business Media Plc. (UBM) is to join a growing exodus of companies from the United Kingdom by shifting its tax base to Ireland, dealing a fresh blow to the Governments tax policies, said The Times.

ROUNDUP Shire Q1 in line, share volatility caused by Vyvanse 'misunderstanding'

Fri, 25 Apr 2008 15:50:51 GMT

LONDON (Thomson Financial) - Shire Pharmaceuticals Plc.'s first-quarter results were largely in line, but a negative reading of the company's guidance for Vyvanse caused a day of volatility, with shares down more than 5 percent in early afternoon trading.

Shire sales beat consensus; 2008 guidance confirmed, sees growth to 2010 UPDATE

Fri, 25 Apr 2008 12:52:05 GMT

(Adds CEO, CFO, analyst comment, fresh share price) LONDON (Thomson Financial) - Shire Pharmaceuticals Plc. posted first-quarter sales of $702 million, up 33 percent and slightly ahead of expectations, with the company reaffirming its financial guidance for this year and predicting positiv

Shire sales beat consensus; 2008 guidance confirmed, sees growth through to 2010

Fri, 25 Apr 2008 11:44:40 GMT

LONDON (Thomson Financial) - Shire Pharmaceuticals Plc. posted first-quarter sales of $702 million, up 33 percent, and slightly ahead of expectations, with the company reaffirming its financial guidance for this year and predicting positive growth through to 2010.

CORRECTION Shire acquires new molecule for orphan drug pipeline from Zymenex

Thu, 24 Apr 2008 08:17:59 GMT

(Corrects to add figure for deal in final paragraph) LONDON (Thomson Financial) - Shire Plc. said it has added to its orphan drug pipeline with the acquisition of a new clinical candidate for Metachromatic Leukodystrophy, a neurological disease, from Danish company Zymenex.

Shire acquires new molecule for its orphan drug pipeline from Zymenex

Thu, 24 Apr 2008 06:28:06 GMT

LONDON (Thomson Financial) - Shire Plc. said it has added to its orphan drug pipeline with the acquisition of a new clinical candidate for Metachromatic Leukodystrophy, a neurological disease, from Danish company Zymenex.

Shire: FDA approves Vyvanse for treatment of ADHD in adults

Wed, 23 Apr 2008 16:18:28 GMT

SAN FRANCISCO (Thomson Financial) - Shire PLC said Wednesday the Food and Drug Administration approved Vyvanse for the treatment of attention deficit hyperactivity disorder in adults, an additional indication.

Shire to introduce a new UK-listed holding company UPDATE

Tue, 15 Apr 2008 10:43:32 GMT

(Adds analyst reaction, live share price) LONDON (Thomson Financial) - Shire Plc. said it is creating a new UK-listed, Jersey-incorporated holding company for the group to help protect its taxation position and better facilitate its financial management.

Shire to introduce a new UK-listed holding company UPDATE

Tue, 15 Apr 2008 08:12:38 GMT

(Updates with further detail from statement) LONDON (Thomson Financial) - Shire Plc. said it is creating a new UK-listed, Jersey incorporated holding company for the group to help protect its taxation position and better facilitate its financial management.

Shire to introduce a new UK-listed holding company

Tue, 15 Apr 2008 06:36:36 GMT

LONDON (Thomson Financial) - Shire Plc. said it is creating a new UK-listed, Jersey incorporated holding company for the group to help protect its taxation position and facilitate its financial management.

Shire, TAP Pharmaceuticals enter 3-year agreement to co-promote Lialda

Wed, 26 Mar 2008 17:40:04 GMT

SAN FRANCISCO (Thomson Financial) - Shire plc said Wednesday it entered a three-year agreement to co-promote Lialda in the United States with TAP Pharmaceutical Products Inc.

Shire says Phase II results for Renovo drug meets one endpoint, misses another

Mon, 03 Mar 2008 12:58:01 GMT

NEW YORK (Thomson Financial) - Shire Plc. Monday said the Phase II results for Juvista met its primary endpoint in a scar revision trial but missed the endpoint in a breast augmentation trial.

Renovo's Juvista shows mixed phase II trial results; Shire says will assess

Mon, 03 Mar 2008 12:39:48 GMT

LONDON (Thomson Financial) - Renovo PLC, the UK biopharmaceutical company, said that its scar reduction medicine Juvista has shown positive results in Phase II trials, however, it failed to show efficacy in a parallel breast augmentation trial.

Shire says non-exec director Mott buys 5,000 ADRs at 58.93 usd/ADR

Tue, 26 Feb 2008 16:53:32 GMT

LONDON (Thomson Financial) - Shire PLC said non-executive director David Mott acquired 5,000 American depository shares on Feb 25, representing 15,000 shares of 0.05 stg each, for an average price of 58.93 usd per ADR.

ROUNDUP Shire delivers sales growth at the top end of consensus

Thu, 21 Feb 2008 15:17:04 GMT

LONDON (Thomson Financial) - Speciality pharmaceutical company Shire PLC's full-year results were at the top end of expectations, with sales increasing by up to 36 pct and Vyvanse performing well in the fourth quarter, analysts said.

Shire FY sales up 36 pct, net loss 1.45 bln usd vs 278 mln profit UPDATE

Thu, 21 Feb 2008 13:43:56 GMT

(Adds recast lede, CEO, detail) LONDON (Thomson Financial) - Speciality pharmaceutical company Shire reported full-year sales of 2.4 bln usd against 1.79 bln last time, with an unadjusted full-year net loss of 1.45 bln usd against a 278 mln profit, while the Vyvanse debate continued unabat

Shire fy sales 2.4 bln usd vs 1.79 bln, net loss 1.45 bln usd vs 278 mln profit

Thu, 21 Feb 2008 12:43:25 GMT

LONDON (Thomson Financial) - Speciality pharmaceutical company Shire reported full-year sales of 2.4 bln usd against 1.79 bln last time, and a full-year net loss of 1.45 bln usd against 278 mln profit.

Shire says Elaprase approved in Mexico for Hunter syndrome, sees H1 2008 launch

Wed, 13 Feb 2008 09:48:11 GMT

LONDON (Thomson Financial) - Specialty biopharmaceutical company Shire says its Hunter syndrome treatment Elaprase has been approved for commercial sale in Mexico, the tenth-largest pharmaceutical market in the world and the first Latin American country to approve the product.

Shire gets FDA approval for three extra dosages of Vyvanse, an ADHD treatment

Thu, 03 Jan 2008 15:04:06 GMT

NEW YORK (Thomson Financial) - Shire PLC Thursday said received approval from the Food and Drug Administration for three additional dosage strengths for Vyvanse, its attention deficit hyperactivity disorder (ADHD) treatment.

Shire pays 25 mln usd upfront for Alba Therapeutics phase II gastro product

Fri, 14 Dec 2007 16:18:05 GMT

LONDON (Thomson Financial) - Shire PLC said it has agreed a licensing deal with Alba Therapeutics to market and develop the latter's phase II gastro-intestinal product AT-1001 outside of the US and Japan for an upfront fee of 25 mln usd.

Renovo net cash at year end 100.7 mln stg, says to last three years UPDATE

Thu, 13 Dec 2007 08:41:00 GMT

LONDON (Thomson Financial) - Wound care specialist Renovo Group said its net cash at Sept 30 2007, the end its financial year, was 100.7 mln stg, and it expects this to last for three years.

Shire names Angus Russell CEO, trading in line with Nov 1 guidance UPDATE

Thu, 13 Dec 2007 08:38:53 GMT

(Update adds analyst comment) LONDON (Thomson Financial) - Shire PLC said Angus Russell, who has been chief financial officer since 1999, will be its new chief executive.

Shire names Angus Russell CEO, says trading in line with Nov 1 guidance

Thu, 13 Dec 2007 07:57:59 GMT

LONDON (Thomson Financial) - Shire PLC said Angus Russell, who has been chief financial officer since 1999, will be its new chief executive.